The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Open accessAbstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with one agent showing benefit only among patients who had a baseline LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter. 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there were little more than 100 events in these studies combined.”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors showed significant reductions in cardiovascular outcomes.9,10”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
In the citing paper
“No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients [274].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18-25% has been observed.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men. 115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Results in studies with PCSK9 inhibitors that included post-ACS/very high-risk patients were promising 115,116 and definitive outcome studies are awaited.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Combination therapy using statin and ezetimibe prevents ASCVD incidence in patients with ACS. (Evidence level 1+, recommendation level: B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“The IMPROVE-IT study636) which enrolled ACS subjects (secondary prevention) with controlled LDL-C levels (50–100 mg/dL) under simvastatin treatment, revealed a significantly lower ASCVD incidence in the group for which ezetimibe was added on to simvastatin treatment.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“Regarding the LDL-C management target, the IMPROVE-IT636) study revealed that lowering the LDL-C level to 53.6 mg/dL using statin–ezetimibe combination therapy suppressed cardiovascular events by 6.4% more than the group that had their LDL-C level controlled at 69.5 mg/dL with statins only.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“(10,11).These agents dramatically reduce LDL-C levels over and above statin therapy, with favorable short-term outcomes data up to 18 months (11,12).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,004
Nowak, C., Salihović, S., Ganna, A., Brandmaier, S., Tukiainen, T., Broeckling, C. D., Magnusson, P. K. E., Prenni, J. E., Wang‐Sattler, R., Peters, A., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006379 · Cited by 29
Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review
Bob‐Manuel, T., Ifedili, I., Reed, G. L., Ibebuogu, U. N., & Khouzam, R. N. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.04.006 · Cited by 33
PCSK9 — A Journey to Cardiovascular Outcomes
Burnett, J. R., & Hooper, A. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1813758 · Cited by 28
Durairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
The functions of apolipoproteins and lipoproteins in health and disease
Ma, Z., Zhong, J., Tu, W., Li, S., & Chen, J. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00218-7 · Cited by 36
An evaluation of alirocumab for the treatment of hypercholesterolemia
Farnier, M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1111759 · Cited by 27
Masana, L., Ibarretxe, D., & Plana, N. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.11.016 · Cited by 27
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
Dent, R. E., Joshi, R., Djedjos, C. S., Legg, J. C., Elliott, M., Geller, M. L., Meyer, D., Somaratne, R. M., Recknor, C. P., & Weiss, R. (2016) · SpringerPlus · doi:10.1186/s40064-016-1892-3 · Cited by 27
Self-citationRecent advances in pathogenesis, assessment, and treatment of atherosclerosis
Spence, J. D. (2016) · F1000Research · doi:10.12688/f1000research.8459.1 · Cited by 27
Novel lipid modifying drugs to lower LDL cholesterol
Cupido, A. J., Reeskamp, L. F., & Kastelein, J. J. P. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000428 · Cited by 30
Poller, W. C., Berger, A., Dreger, H., Morgera, S., & Enke-Melzer, K. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.007 · Cited by 27
Szymański, F. M., Barylski, M., Cybulska, B., Wożakowska−Kapłon, B., Krasiński, Z., Mamcarz, A., Widecka, K., Platek, A. E., Dudek, D., Mickiewicz, A., et al. (2018) · Cardiology Journal · doi:10.5603/cj.2018.0141 · Cited by 28
Ascaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.06.001 · Cited by 27
Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Hu, J., Lei, H. C., Liu, L., & Xu, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812368 · Cited by 28
Gulizia, M. M., Colivicchi, F., Ricciardi, G., Giampaoli, S., Maggioni, A. P., Averna, M. R., Graziani, M. S., Ceriotti, F., Mugelli, A., Rossi, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux029 · Cited by 27
A Clinical Guide to Combination Lipid-Lowering Therapy
Russell, C. E., Sheth, S., & Jacoby, D. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0721-2 · Cited by 27
Fan, T., Yang, Y., Zeng, Q., Wang, X., Wei, W., Guo, X., Zhao, L., Song, D., Wang, Y., Wang, L., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104994 · Cited by 27
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom, D. J., Dent, R. E., Castro, R. D. C., & Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s102564 · Cited by 27
Self-citationMilionis, H. J., Barkas, F., Ntaios, G., Papavasileiou, V., Vemmos, K. N., Michel, P., & Elisaf, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.023 · Cited by 26
Peng, W., Qiang, F., Peng, W., Qian, Z., Ke, Z., Yi, L., Zhong, J., & Chong-Rong, Q. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.239 · Cited by 26
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U., & Luijendijk, H. J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1787832 · Cited by 27
PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
Wu, D., Pan, Y., Yang, S., Li, C., Zhou, Y., Wang, Y., Chen, X., Zhou, Z., Liao, Y., & Qiu, Z. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07041-6 · Cited by 27
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 26
Xu, M., Zhu, X., Wu, J., Zhang, Y., Zhao, D., Wang, X., Ding, Y., Cao, Y., Li, C., Hu, W. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02208-w · Cited by 27
Puri, R., Mehta, V., Duell, P. B., Wangnoo, S. K., Rastogi, A., Mohan, V., Zargar, A. H., Kalra, S., Sahoo, A., Iyengar, S. S., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.11.002 · Cited by 30
Jaworski, K., Jankowski, P., & KOSIOR, D. A. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.65239 · Cited by 27
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
Lipid-lowering treatment in peripheral artery disease
Katsiki, N., Giannoukas, A. D., Athyros, V. G., & Mikhailidis, D. P. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.003 · Cited by 26
Okuyama, H., Hamazaki, T., Hama, R., Ogushi, Y., Kobayashi, T., Ohara, N., & Uchino, H. (2018) · Pharmacology · doi:10.1159/000486374 · Cited by 26
A clinically applicable adjuvant for an atherosclerosis vaccine in mice
Kobiyama, K., Vassallo, M., Mitzi, J., Winkels, H., Pei, H., Kimura, T., Miller, J. F., Wolf, D., & Ley, K. F. (2018) · European Journal of Immunology · doi:10.1002/eji.201847584 · Cited by 26
Genetic Polymorphisms in Sepsis and Cardiovascular Disease
Nakada, T., Takahashi, W., Nakada, E., Shimada, T., Russell, J. A., & Walley, K. R. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.01.003 · Cited by 26
AlTurki, A., Marafi, M., Dawas, A., Dubé, M., Vieira, L., Sherman, M. H., Grégoire, J. C., Thanassoulis, G., Tardif, J., & Huynh, T. T. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.011 · Cited by 26
White, C. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015608487 · Cited by 25
Tian, W., Cao, H., Li, X., Gong, X., Yu, X., Li, D., Xie, J., Bai, Y., Zhang, D., Li, X., et al. (2025) · CNS Drugs · doi:10.1007/s40263-024-01145-5 · Cited by 25
A New Approach to PCSK9 Therapeutics
Wang, N., & Tall, A. R. (2017) · Circulation Research · doi:10.1161/circresaha.117.310610 · Cited by 27
Page, M. M., & Watts, G. F. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13070 · Cited by 27
Akin, A. C., Barrila, M. T., Brandt, T. A., Dechert‐Schmitt, A. R., Dubé, P., Ford, D. D., Kamlet, A. S., Limberakis, C., Pearsall, A., Piotrowski, D. W., et al. (2017) · Organic Process Research & Development · doi:10.1021/acs.oprd.7b00304 · Cited by 25
Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know
Paraskevas, K. I., Veith, F. J., Eckstein, H., Ricco, J., & Mikhailidis, D. P. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.176 · Cited by 25
Khan, S. U., Khan, M. U., Virani, S. S., Khan, M. S., Khan, M. Z., Rashid, M. O., Kalra, A., Alkhouli, M. A., Blaha, M. J., Blumenthal, R. S., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa093 · Cited by 29
Lipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 26
Management of patients with statin intolerance
Martirossian, A. N., & Goldberg, A. C. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101714 · Cited by 27
Page, M. M., Stefanutti, C., Sniderman, A. D., & Watts, G. F. (2015) · Clinical Science · doi:10.1042/cs20140755 · Cited by 25
Lowering cholesterol in chronic kidney disease: is it safe and effective?
Wong, M. G., Wanner, C., Knight, J. F., & Perkovic, V. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv393 · Cited by 25
Identifying familial hypercholesterolemia in acute coronary syndrome
Gencer, B., & Nanchen, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000311 · Cited by 25
Feng, Z., Li, H., Bei, W., Guo, X., Wang, K., Yi, S., Luo, D., Li, X., Chen, S., Ran, P., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22712 · Cited by 25
Vrablı́k, M., Rašlová, K., Vohnout, B., Blaha, V., Satny, M., Kyselák, O., Vaclová, M., Urbánek, R., Mašková, J., Soška, V., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.008 · Cited by 25
Preventive Role of Tetraspanin CD9 in Systemic Inflammation of Chronic Obstructive Pulmonary Disease
Takeda, Y., Suzuki, M., Jin, Y., & Tachibana, I. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0122tr · Cited by 23
Carroll, C., Tappenden, P., Rafia, R., Hamilton, J. A., Chambers, D., Clowes, M., Durrington, P. N., Qureshi, N., & Wierzbicki, A. S. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0492-6 · Cited by 24
Bococizumab for the treatment of hypercholesterolaemia
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1279602 · Cited by 24
Pirro, M., Bianconi, V., Francisci, D., Schiaroli, E., Bagaglia, F., Sahebkar, A., & Baldelli, F. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13273 · Cited by 24
Current pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 24
Kheirkhah, A., Lamina, C., Rantner, B., Kollerits, B., Stadler, M., Pohlhammer, J., Klein-Weigel, P. F., Fraedrich, G., & Kronenberg, F. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.025 · Cited by 24
The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis
Qin, J., Liu, L., Su, X. D., Wang, B. B., Fu, B. S., Cui, J., & Liu, X. Y. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.026 · Cited by 26
Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis
Nguyen, T. K., Paone, S., Chan, E., Poon, I. K. H., Baxter, A. A., Thomas, S. R., & Hulett, M. D. (2022) · Cells · doi:10.3390/cells11203198 · Cited by 26
Hypercholesterolemia and the Increased Risk of Vascular Dementia: a Cholesterol Perspective
Shang, G., Shao, Q., Lv, K., Xu, W., Ji, J., Fan, S., Kang, X., Cheng, F., Wang, X., & Wang, Q. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01217-3 · Cited by 24
Franchini, M., Capuzzo, E., & Liumbruno, G. M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2015.0163-15 · Cited by 24
Familial Hypercholesterolemia: Advances in Recognition and Therapy
Cartier, J. L., & Goldberg, A. C. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.006 · Cited by 24
Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons
Bajaj, N. S., Patel, N., Kalra, R., Ahmad, A., Venkatraman, A., Arora, G., & Arora, P. K. (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx037 · Cited by 25
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
Cicero, A. F. G., Morbini, M., Bove, M., D’Addato, S., Fogacci, F., Rosticci, M., & Borghi, C. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1190326 · Cited by 23
Jacobson, T. A., Khan, M. A. S., Maki, K. C., Brinton, E. A., & Cohen, J. D. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.006 · Cited by 23
Cho, L., Dent, R. E., Stroes, E. S. G., Stein, E. A., SULLIVAN, D. R., Ruzza, A., Flower, A., Somaratne, R. M., & Rosenson, R. S. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6817-7 · Cited by 23
Self-citationPharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Choi, J. Y., & Na, J. O. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.183 · Cited by 26
LDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis
Masson, W. M., Lobo, M., Siniawski, D. A., Masson, G., Cobo, A. L., & Molinero, G. B. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105655 · Cited by 23
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 35
Manejo do risco cardiovascular: dislipidemia
Izar, M. C. D. O., Fonseca, F. A. H., Faludi, A. Á., de Araújo, D. B., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-19 · Cited by 33
PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function
Kheirkhah, A., Lamina, C., Kollerits, B., Schachtl‐Riess, J. F., Schultheiß, U. T., Forer, L., Sekula, P., Kotsis, F., Eckardt, K., & Kronenberg, F. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01230122 · Cited by 23
Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease
Kon, V., Shelton, E. L., Pitzer, A. L., Yang, H., & Kirabo, A. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01206-4 · Cited by 23
Sobczyk, M., Zheng, J., Smith, G. D., & Gaunt, T. R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072087 · Cited by 26
Masana, L., Ibarretxe, D., & Plana, N. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.11.014 · Cited by 23
Alkhalil, M., Biasiolli, L., Chai, J. T., Galassi, F., Li, L., DARBY, C. R., Halliday, A. W., Hands, L. J., Magee, T. R., Perkins, J. M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181668 · Cited by 23
Hachem, A. A., Hariri, E. H., Saoud, P., Lteif, C., Lteif, L., & Welty, F. K. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170804150954 · Cited by 23
Bai, J., Gong, L., Li, Q., & Wang, Z. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.004 · Cited by 25
Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
Rymer, J. A., Mues, K. E., Monda, K. L., Bratton, E. W., Wirtz, H. S., Okerson, T. E., Overman, R. A., Brookhart, M. A., Muntner, P., & Wang, T. Y. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014347 · Cited by 23
Khan, S. U., & Michos, E. D. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100013 · Cited by 23
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 25
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 23
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a)
Ferdinand, K. C., & Nasser, S. A. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6588-3 · Cited by 24
Prescription omega-3 fatty acid products: Considerations for patients with diabetes mellitus
Avallone, L., Shaikh, A., Hassan, A., & Tajuddin, N. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s97036 · Cited by 22
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
Oleaga, C., Hay, J., Gurcan, E., David, L. L., Mueller, P. A., Tavori, H., Shapiro, M. D., Pamir, N., & Fazio, S. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000964 · Cited by 22
Tufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 22
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
Fusco, S. A. D., Maggioni, A. P., Bernelli, C., Perone, F., Marzo, V. D., Conte, E., Musella, F., Uccello, G., Luca, L. D., Gabrielli, D., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311375 · Cited by 24
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 24
Khan, S. U., Riaz, H., Rahman, H., Khan, M. U., Khan, M. S., Alkhouli, M. A., Kaluski, E., Leucker, T. M., & Blaha, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.014 · Cited by 24
Effects of immunisation against PCSK9 in mice bearing melanoma
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.91291 · Cited by 24
Landmesser, U., Lindgren, P., Hagström, E., van Hout, B., Villa, G., Pemberton-Ross, P. J., Arellano, J., Svensson, M. K. E., Sibartie, M., & Fonarow, G. C. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa072 · Cited by 22
Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
Návar, A. M., Wang, T. Y., Goldberg, A. C., Robinson, J. G., Roger, V. L., Wilson, P. W. F., Virani, S. S., Elassal, J., Lee, L. V., Webb, L. E., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.08.002 · Cited by 21
Self-citationPCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
Rallidis, L. S., & Lekakis, J. P. (2016) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2016.03.002 · Cited by 21
Katsiki, N., Athyros, V. G., Mikhailidis, D. P., & Mantzoros, C. S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.007 · Cited by 21
Ganjali, S., Momtazi‐Borojeni, A. A., Banach, M., Kovanen, P. T., Gotto, A. M., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.014 · Cited by 21
Shi, Q., Liu, S., Krousel-Wood, M. A., Shao, H., Fonseca, V. A., & Shi, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.013 · Cited by 21
The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia
Patel, R. S., Scopelliti, E. M., & Olugbile, O. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018771670 · Cited by 21
Cognitive Function in a Randomized Trial of Evolocumab
Giugliano, R. P., Mach, F., Zavitz, K. H., Kurtz, C. E., Im, K., Kanevsky, E., Schneider, J., Wang, H., KEECH, A. C., Pedersen, T. R., et al. (2018) · Yearbook of pediatric endocrinology · doi:10.1530/ey.15.12.14 · Cited by 21
Self-citationLiang, Z., Chen, Q., Yang, F., Yan, X., Zhang, X., Xue, C., Fang, F., & Zhao, Q. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07079-6 · Cited by 22
Raccah, B. H., Yanovsky, A., Treves, N., Rotshild, V., Renoux, C., Danenberg, H. D., Eliaz, R., & Matok, I. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.025 · Cited by 21
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry
Cordero, A., Olmo, M. R. F., Quiroga, G. A. C., Romero‐Menor, C., Fácila, L., Seijas‐Amigo, J., Rondán, J., Sandín, M., Rodríguez‐Mañero, M., Mora, M. C. B., et al. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13863 · Cited by 21
The Role of a Coronary Artery Calcium Scan in Type 1 Diabetes
Burge, M. R., Eaton, R. P., & Schade, D. S. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0110 · Cited by 21
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East
Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 22
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Preiss, D., & Mafham, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4178-y · Cited by 21
Zhao, Y., Delaney, J. A., Quek, R. G. W., Gardin, J. M., Hirsch, C. H., Gandra, S. R., & Wong, N. D. (2016) · Clinical Cardiology · doi:10.1002/clc.22546 · Cited by 21
Metadata
- Authors
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A.
- Affiliations
- University of Iowa (US)
- Harvard University (US)
- University of the Witwatersrand (ZA)
- University of Cape Town (ZA)
- Houston Methodist (US)
- Amgen (United States) (US)
- Jacksonville Center for Clinical Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1500-1509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238580056
- Semantic Scholar
- 3a2aa2d61647c779adc7c8fa42c75fb373940128
- Cited by
- 1,509
- References
- 26
- Citations by year
- 2026: 44 · 2025: 54 · 2024: 71 · 2023: 73 · 2022: 88 · 2021: 91 · 2020: 104 · 2019: 148 · 2018: 152 · 2017: 261 · 2016: 277 · 2015: 141
- FWCI
- 279.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- evolocumab, PCSK9 inhibitors, LDL cholesterol lowering, cardiovascular events, lipid-lowering therapy, drug efficacy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
